Back to News
Market Impact: 0.25

Validea Detailed Fundamental Analysis

HUMNDAQ
Company FundamentalsAnalyst InsightsCapital Returns (Dividends / Buybacks)Healthcare & Biotech
Validea Detailed Fundamental Analysis

Validea's guru fundamental report indicates Humana (HUM), a large-cap healthcare facilities stock, received a 70% rating from Meb Faber's Shareholder Yield Investor model. This model prioritizes companies returning cash to shareholders via dividends, buybacks, and debt paydown; however, despite passing quality, valuation, and relative strength criteria, HUM notably failed the specific 'Net Payout Yield' and 'Shareholder Yield' tests, placing it below the 80% threshold for 'some interest' within the strategy.

Analysis

According to a Validea fundamental report, Humana Inc. (HUM), a large-cap growth stock in the healthcare facilities sector, scored 70% based on Meb Faber's Shareholder Yield Investor model. This score is below the 80% threshold that typically indicates strategic interest. The analysis presents a notable conflict: while HUM passed the model's criteria for 'Quality and Debt', 'Valuation', and 'Relative Strength', it specifically failed on the core tenets of the strategy, namely 'Net Payout Yield' and 'Shareholder Yield'. This suggests that while the company exhibits positive underlying fundamentals and favorable valuation, its current capital return program—comprising dividends, share buybacks, and debt reduction—does not meet the specific, aggressive benchmarks required by this particular investment model. The resulting mixed sentiment signal accurately reflects this dichotomy between general financial health and a specific weakness in shareholder-return metrics.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request a Demo

Market Sentiment

Overall Sentiment

mixed

Sentiment Score

-0.10

Ticker Sentiment

HUM0.20
NDAQ0.00

Key Decisions for Investors

  • Investors strictly following a shareholder yield strategy should note HUM's failure on the key payout metrics, indicating it may not currently align with their mandate for high capital returns.
  • Value or quality-focused investors may find the positive ratings on 'Quality and Debt' and 'Valuation' to be compelling entry points, provided that direct shareholder yield is a lower priority.
  • Given the mixed signals, it is prudent to monitor Humana's future capital allocation announcements, as any significant increase in buybacks or dividends could materially improve its score within this model and attract yield-seeking investors.